NCT01150981View on ClinicalTrials.gov

Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Metabolic SyndromeInsulin Resistance
Interventions
DRUG

Rosiglitazone

One 8mg capsule daily for 6 weeks.

DRUG

Placebo

One capsule daily for 6 weeks.

Trial Locations (1)

01655

UMass Medical School, Worcester

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Massachusetts, Worcester

OTHER